CCM
PCRX icon

Cinctive Capital Management’s Pacira BioSciences PCRX Stock Holding History

Cinctive Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-87,487
Closed -$4.65M – 503
2022
Q3 		$4.65M Buy
87,487
+28,388
+48% +$1.58M 0.19% 186
2022
Q2 		$3.44M Buy
+59,099
New +$3.87M 0.14% 229

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Cinctive Capital Management's PCRX Position: Q4 2022 in Review

Cinctive Capital Management sold out of Pacira BioSciences (PCRX) in Q4 2022, closing a stake of 87,487 shares — an estimated $4.65M sold.

Cinctive Capital Management first reported a position in PCRX in Q2 2022 and held it in 2 quarters. The position peaked at $4.65M in Q3 2022. 273 funds tracked by Wall St. Rank hold PCRX as of Q4 2022.

  • Cinctive Capital Management reported no remaining Pacira BioSciences position as of Q4 2022 after selling out during the quarter.
  • Cinctive Capital Management sold 87,487 Pacira BioSciences shares in Q4 2022, an estimated $4.65M.
  • Cinctive Capital Management first reported a position in Pacira BioSciences in Q2 2022 and held it in 2 quarters.
  • Cinctive Capital Management's Pacira BioSciences position peaked at $4.65M in Q3 2022.
  • 273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2022.

Based on Cinctive Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.